FDA Schedules ODAC Meeting on Tazemetostat for Epithelioid Sarcoma
The FDA has scheduled an Oncology Drugs Advisory Committee hearing for December 18, 2019, to discuss data supporting a new drug application for tazemetostat as a treatment for patients with metastatic or locally advanced epithelioid sarcoma that is ineligible for curative surgery.
Source: OncLive